Sichenzia Ross Ference LLP Represents Genetic Technologies Limited in $1.44 Million Registered Direct Offering
Press Release – New York, NY – April 23, 2020 – Sichenzia Ross Ference LLP today announced that it represented Genetic Technologies Limited (NASDAQ: GENE), a leader in the development of genetic risk assessment tests, in a registered direct offering of 722,502 American Depositary Shares (ADSs), each representing 600 of the Company’s ordinary shares, at a purchase price of $2.00 per ADS.
The ADSs had been registered on a registration statement on Form F-3 (File No. 333-237152) declared effective by the Securities and Exchange Commission on March 23, 2020.
The Sichenzia Ross Ference LLP team was led by partners Darrin Ocasio and Avital Perlman, counsel Jeff Cahlon, and associate Yian Pan.
- Sichenzia Ross Ference LLP Represents EF Hutton in $8.4 Million Simultaneous Registered Direct Offering and Private Placement of Securities of Nemaura Medical, Inc. - February 3, 2023
- Sichenzia Ross Ference LLP Represents Verb Technology Company, Inc. in $7.2 Million Underwritten Public Offering of Common Stock - January 26, 2023
- Sichenzia Ross Ference LLP Represents Jupiter Wellness, Inc. in $4.1 Million Registered Direct Offering and Concurrent Private Placement of Warrants - January 24, 2023